`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 1 of 6 PagelD #: 21796
`
`EXHIBIT 3
`EXHIBIT 3
`
`
`
`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 2 of 6 PageID #: 21797
`
`Haunschild, Philip
`From:
`Li, Yan-Xin <yanxin.li@kirkland.com>
`Sent:
`Thursday, May 23, 2024 8:19 PM
`To:
`Haunschild, Philip; Genevant Team; 'Arbutus_MoFo'; *jshaw@shawkeller.com; 'Karen E. Keller
`(kkeller@shawkeller.com)'; 'Nate R. Hoeschen (nhoeschen@shawkeller.com)'; 'Emily DiBenedetto'
`#KEModernaSpikevaxService; 'Jack Blumenfeld (jblumenfeld@morrisnichols.com)'; 'Egan, Brian P.';
`'Travis J. Murray (tmurray@morrisnichols.com)'
`RE: Arbutus v. Moderna (22-252) // Supplemental Interrogatory Response (No. 18)
`
`Subject:
`
`Cc:
`
`[CONTAINS INFORMATION DESIGNATED HIGHLY CONFIDENTIAL BY MODERNA]
`
`Hi Philip:
`
`Thanks for your emails, and for the meet and confer last week. We have considered our discussions and the issues raised in
`Plaintiffs’ May 9, 2024 letter. We disagree as to any alleged prejudice to Plaintiffs. By contrast, Moderna has undergone an
`extremely burdensome investigation, while still fully complying with its notice and confidentiality obligations to foreign
`governments, in providing information responsive to the non‐objectionable scope of Plaintiffs’ Interrogatory No. 18 (and 19–21)
`pertaining to “vaccines manufactured abroad and sold abroad.” D.I. 229.
`
`The crux of Plaintiffs’ May 9, 2024 letter appears to focus only on “negotiations” as identified in subpart (3) of Interrogatory No. 18.
`Plaintiffs should know, yet ignore, that “pricing and contracting negotiations in the United States alone do not constitute or
`transform [] extraterritorial activities into a sale within the United States” when substantial activities of a sales transaction, such as
`delivery and performance under the sales contract, occur entirely outside the United States—as is the case here. Halo Elecs., Inc. v.
`Pulse Elecs., Inc., 831 F.3d 1369, 1378 (Fed. Cir. 2016). Indeed, U.S. patent laws are to be understood against a background
`presumption against extraterritorial reach. Microsoft Corp. v. AT & T Corp., 550 U.S. 437, 444 (2007).
`
`Your identification of certain documents as purportedly showing “substantial sales activity” in the United States before (or even
`after) June 2021 mischaracterizes both the documents and the facts that Plaintiffs have been provided by Moderna.
`
`
`
`
` This is incorrect.
`
`There is no “sales in China.”
`
`
`
`
`
`
`
`Your reliance on Apeldyn and McGinley presupposes that Plaintiffs have actually demonstrated relevance for OUS discovery, given
`the strong presumption against any extraterritorial reach of U.S. patent law. Plaintiffs have failed to do so, and continue to base
`their broad sweeping discovery demands on mere suspicion and speculation. Tessera, Inc. v. Broadcom Corp., No. 16‐380, 2017 WL
`4876215, at *5 (D. Del. Oct. 24, 2017). In view of Plaintiffs’ failure, Moderna does not agree to produce its pre‐June 2021 or post‐
`June 2021 OUS supply agreements.
`
`Best regards,
`Yan‐Xin
`
`Yan-Xin Li
`------------------------------------------------------------
`KIRKLAND & ELLIS LLP
`555 California Street, San Francisco, CA 94104
`T +1 415 439 1618
`------------------------------------------------------------
`yanxin.li@kirkland.com
`
`
`1
`
`
`
`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 3 of 6 PageID #: 21798
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`From: Haunschild, Philip <phaunschild@wc.com>
`Sent: Tuesday, May 21, 2024 7:40 AM
`To: Li, Yan‐Xin <yanxin.li@kirkland.com>; Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo'
`<Arbutus MoFo@mofo.com>; *jshaw@shawkeller.com <jshaw@shawkeller.com>; 'Karen E. Keller
`(kkeller@shawkeller.com)' <kkeller@shawkeller.com>; 'Nate R. Hoeschen (nhoeschen@shawkeller.com)'
`<nhoeschen@shawkeller.com>; 'Emily DiBenedetto' <edibenedetto@shawkeller.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; 'Jack Blumenfeld
`(jblumenfeld@morrisnichols.com)' <jblumenfeld@morrisnichols.com>; 'Egan, Brian P.' <began@morrisnichols.com>;
`'Travis J. Murray (tmurray@morrisnichols.com)' <tmurray@morrisnichols.com>
`Subject: RE: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response (No. 18)
`
` Hi Yan‐Xin,
`
`It is now just over a week from the close of fact discovery, and we still have not heard back from Moderna regarding the
`issues raised in our May 9 letter. Can you please get back to us by COB tomorrow? Thank you.
`
`Philip N. Haunschild
`Associate | Williams and Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202‐434‐5979 | phaunschild@wc.com | www.wc.com
`
`From: Haunschild, Philip
`Sent: Wednesday, May 15, 2024 6:44 PM
`To: 'Li, Yan‐Xin' <yanxin.li@kirkland.com>; Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo'
`<Arbutus MoFo@mofo.com>; '*jshaw@shawkeller.com' <jshaw@shawkeller.com>; 'Karen E. Keller
`(kkeller@shawkeller.com)' <kkeller@shawkeller.com>; 'Nate R. Hoeschen (nhoeschen@shawkeller.com)'
`<nhoeschen@shawkeller.com>; 'Emily DiBenedetto' <edibenedetto@shawkeller.com>
`Cc: '#KEModernaSpikevaxService' <KEModernaSpikevaxService@kirkland.com>; 'Jack Blumenfeld
`(jblumenfeld@morrisnichols.com)' <jblumenfeld@morrisnichols.com>; 'Egan, Brian P.' <began@morrisnichols.com>;
`'Travis J. Murray (tmurray@morrisnichols.com)' <tmurray@morrisnichols.com>
`Subject: RE: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response (No. 18)
`
`Hi Yan‐Xin,
`
`Thank you for the meet‐and‐confer yesterday. We understand from our discussion that Moderna will be reverting
`regarding the issues we have raised in our May 9 letter in the next few days. We would ask for your response no later
`than COB Thursday, May 16, as Plaintiffs continue to be prejudiced by the delay in providing these materials.
`
`As to Moderna’s proposal to put up Mr. Brackmann tomorrow as a 30(b)(6) witness on Topics 41 – 43 with the limitation
`that he would only speak to the content of Moderna’s response to Interrogatory No. 18, we cannot accept Moderna’s
`proposed limitations. We understand that Moderna is only proposing to designate Mr. Brackmann on the content of
`Moderna’s interrogatory response, and will not put up a witness on the further supplements to Interrogatory No. 18
`that we are requesting to obtain a complete answer, or to address the documents that Moderna has not yet
`produced. Plaintiffs cannot accept these unreasonable limitations, which amount to nothing more than the witness
`repeating what Moderna’s lawyers wrote in the interrogatory responses. Plaintiffs are entitled to test those responses
`in discovery, including with documents that Moderna has yet to produce. As we said on the call, however, we are willing
`to work with Moderna to reach a limited scope of deposition regarding the documents Moderna produces and/or the
`facts in further supplements to Interrogatory No. 18, as we have requested.
`
`With respect to Moderna’s production of board materials, we understand that Moderna is still collecting and preparing
`these materials for production. We reiterate what we said on the call: Moderna’s delay in producing these materials
`has been substantial and unjustified. Plaintiffs cannot be expected to depose Moderna’s executive witnesses next week
`2
`
`
`
`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 4 of 6 PageID #: 21799
`
`in the absence of these materials and without adequate time to review them. Moderna has been under Court order to
`produce these materials for nearly three months, and Plaintiffs cannot be expected to review them in the short window
`of time remaining. Accordingly, we will reserve the right to recall Moderna’s witnesses who will be deposed this week
`and next. We again ask that these documents (or any that are ready) be produced immediately and without further
`delay.
`
`Thank you,
`
`
`Philip N. Haunschild
`Associate | Williams and Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202‐434‐5979 | phaunschild@wc.com | www.wc.com
`
`From: Haunschild, Philip
`Sent: Monday, May 13, 2024 10:25 AM
`To: Li, Yan‐Xin <yanxin.li@kirkland.com>; Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo'
`<Arbutus MoFo@mofo.com>; *jshaw@shawkeller.com <jshaw@shawkeller.com>; Karen E. Keller
`(kkeller@shawkeller.com) <kkeller@shawkeller.com>; Nate R. Hoeschen (nhoeschen@shawkeller.com)
`<nhoeschen@shawkeller.com>; Emily DiBenedetto <edibenedetto@shawkeller.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Jack Blumenfeld
`(jblumenfeld@morrisnichols.com) <jblumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`Travis J. Murray (tmurray@morrisnichols.com) <tmurray@morrisnichols.com>
`Subject: RE: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response (No. 18)
`
`Hi Yan‐Xin,
`
`Plaintiffs are available at 5:30 p.m. ET tomorrow. We can use the following dial‐in:
`
`Dial-in by phone
`+1 332-249-0718,,799706732# United States, New York City
`Find a local number
`Phone conference ID: 799 706 732#
`
`
`Thank you,
`
`Philip N. Haunschild
`Associate | Williams and Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202‐434‐5979 | phaunschild@wc.com | www.wc.com
`
`From: Li, Yan‐Xin <yanxin.li@kirkland.com>
`Sent: Monday, May 13, 2024 9:09 AM
`To: Haunschild, Philip <phaunschild@wc.com>; Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo'
`<Arbutus MoFo@mofo.com>; *jshaw@shawkeller.com <jshaw@shawkeller.com>; Karen E. Keller
`(kkeller@shawkeller.com) <kkeller@shawkeller.com>; Nate R. Hoeschen (nhoeschen@shawkeller.com)
`<nhoeschen@shawkeller.com>; Emily DiBenedetto <edibenedetto@shawkeller.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Jack Blumenfeld
`(jblumenfeld@morrisnichols.com) <jblumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`Travis J. Murray (tmurray@morrisnichols.com) <tmurray@morrisnichols.com>
`Subject: RE: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response (No. 18)
`
`3
`
`
`
`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 5 of 6 PageID #: 21800
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Philip:
`
`As to your demand for a meet and confer with Delaware counsel, we are not available today. We can be available Tuesday, May 14
`at or after 5:30 pm ET.
`
`
`Yan-Xin Li
`------------------------------------------------------------
`KIRKLAND & ELLIS LLP
`555 California Street, San Francisco, CA 94104
`T +1 415 439 1618
`------------------------------------------------------------
`yanxin.li@kirkland.com
`
`From: Haunschild, Philip <phaunschild@wc.com>
`Sent: Thursday, May 9, 2024 3:44 PM
`To: Li, Yan‐Xin <yanxin.li@kirkland.com>; Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo'
`<Arbutus MoFo@mofo.com>; *jshaw@shawkeller.com <jshaw@shawkeller.com>; Karen E. Keller
`(kkeller@shawkeller.com) <kkeller@shawkeller.com>; Nate R. Hoeschen (nhoeschen@shawkeller.com)
`<nhoeschen@shawkeller.com>; Emily DiBenedetto <edibenedetto@shawkeller.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Jack Blumenfeld
`(jblumenfeld@morrisnichols.com) <jblumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`Travis J. Murray (tmurray@morrisnichols.com) <tmurray@morrisnichols.com>
`Subject: RE: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response (No. 18)
`
` Hi Yan‐Xin,
`
`Please see the attached correspondence.
`
`Thank you,
`
`Philip N. Haunschild
`Associate | Williams and Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202‐434‐5979 | phaunschild@wc.com | www.wc.com
`
`From: Li, Yan‐Xin <yanxin.li@kirkland.com>
`Sent: Friday, May 3, 2024 7:59 PM
`To: Genevant Team <GenevantTeam@wc.com>; 'Arbutus_MoFo' <Arbutus_MoFo@mofo.com>;
`*jshaw@shawkeller.com <jshaw@shawkeller.com>; Karen E. Keller (kkeller@shawkeller.com)
`<kkeller@shawkeller.com>; Nate R. Hoeschen (nhoeschen@shawkeller.com) <nhoeschen@shawkeller.com>; Emily
`DiBenedetto <edibenedetto@shawkeller.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Jack Blumenfeld
`(jblumenfeld@morrisnichols.com) <jblumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`Travis J. Murray (tmurray@morrisnichols.com) <tmurray@morrisnichols.com>
`Subject: Arbutus v. Moderna (22‐252) // Supplemental Interrogatory Response
`
`Counsel:
`
`Attached please find:
`
`
`
`
` DEFENDANTS’ FIRST SUPPLEMENTAL OBJECTIONS AND RESPONSES TO PLAINTIFFS’ FOURTH SET OF INTERROGATORIES (NO.
`18)
`
`4
`
`
`
`Case 1:22-cv-00252-MSG Document 361-5 Filed 06/21/24 Page 6 of 6 PageID #: 21801
`
`
`Best regards,
`Yan‐Xin
`
`Yan-Xin Li
`------------------------------------------------------------
`KIRKLAND & ELLIS LLP
`555 California Street, San Francisco, CA 94104
`T +1 415 439 1618
`------------------------------------------------------------
`yanxin.li@kirkland.com
`
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only
`for the use of the addressee. It is the property of the multi-national law firm Kirkland & Ellis LLP and/or its affiliated entities. Unauthorized use, disclosure
`or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please
`notify us immediately by return email or by email to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all
`attachments.
`
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is privileged and
`confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the
`message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank
`you.
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only
`for the use of the addressee. It is the property of the multi-national law firm Kirkland & Ellis LLP and/or its affiliated entities. Unauthorized use, disclosure
`or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please
`notify us immediately by return email or by email to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all
`attachments.
`
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only
`for the use of the addressee. It is the property of the multi-national law firm Kirkland & Ellis LLP and/or its affiliated entities. Unauthorized use, disclosure
`or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please
`notify us immediately by return email or by email to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all
`attachments.
`
`
`5
`
`